Learning Objectives:
- Explore the clinical role for TDM and pre-medication with asparaginase therapy
- Understand how TDM assists to identify silent inactivation
- Appreciate the role pre-medication to reduce infusion and hypersensitivity reactions
Thursday, February 16, 2023
7:00 PM – 8:00 PM ET
To encourage an interactive webinar, please complete the questionnaire upon registration below.
About the Faculty
Andre Schuh, MD, FRCPC
Moderator & Speaker
Dr. Andre Schuh obtained his MD degree at the University of Toronto, Ontario, Canada, in 1983, and thereafter received subspecialty certification in Internal Medicine (1987) and Hematology (1988), followed by a four year Molecular Biology Fellowship.
Dr. Schuh has been a staff physician at the University Health Network/Princess Margaret Cancer Centre, Toronto, Ontario, since 1992, where he has long focused on acute leukemia and MDS. He was the head of the leukemia program at Princess Margaret from 2010-2014, and from 2012-2018, was Medical Director, Malignant Hematology.
His current interests include Acute Leukemia management and clinical trials (especially in the older patient), and the development of Canadian province- and country-wide leukemia management strategies.
Jim Whitlock, MD
Speaker
Sponsorship
This program has been made possible through unrestricted support from Servier.
88515705351